PETER BRENDERSPresident and CEO

BIOTECanada

Peter Brenders joined BIOTECanada as President & CEO in February 2005. Previously, he worked

in health and corporate affairs in senior management roles at Genzyme Canada and Schering-

Plough Canada. Mr. Brenders has also worked in the Ontario Ministry of Health and in the health

consulting practice at KPMG.

Mr. Brenders is currently a member of the Advisory Board for the National Research Council’s (NRC)

Institute for Marine Biosciences and the NRC’s Institute for Nutrisciences and Health, a member of

the Department of Foreign Affairs and International Trade’s Life Sciences Advisory Board and the

Industry Advisor for the Atlantic Canada Opportunity Agency’s Atlantic Innovation Fund Committees

for Aquaculture and Biotechnology Sector and Health and Medical Sector. He is a member of the

Advisory Council for Algonquin College’s biotechnology program, and has served as a member of the

Privy Council Office’s Reference Group on Regulating, as a Board member and Treasurer of the

Registered Nurses Association of Ontario Foundation, and has served as the Chair of its Toronto

Chapter of the Canadian College of Health Services Executives.

Mr. Brenders regularly offers industry presentations at domestic and international events and conducts regular lectures to

graduate classes at McMaster University. He received his MBA in Health Services Management from McMaster University. Prior

to his brief work in basic research at the Robarts Research Institute, he received his honours BSc in Pharmacology and Toxicology

from the University of Western Ontario.

MICHAEL BROGRANPresident

IMS Brogan - A Unit of IMS

Michael Brogan, President of IMS Brogan, is responsible for the Canadian business unit of IMS

Health. He has lead the company’s Canada operations since February 2011.

Michael joined the organization in 2010 as Vice-President, Sales and Marketing following the merger

of IMS’s Canadian business with Brogan, Inc., a market research and consulting firm serving

Canada’s healthcare market.

Prior to IMS, Michael held roles of increasing responsibility at Brogan, Inc., leading the company’s

sales, marketing, product management and consulting functions. As lead business architect, he also

drove the design and development of the company’s innovative offerings portfolio serving

government, payers and pharmaceutical companies. He joined the company in 1998. Michael holds

a bachelor’s degree in journalism from Carleton University.

DEBORAH BROWNManaging Director/President

EMD Canada Inc.

Deborah Brown is the Canadian President of EMD Canada, an affiliate of Merck Serono and Merck KGaA. Deborah completed

undergraduate and graduate studies in science and business from the University of Guelph and the Richard Ivey School of

Business at the University of Western Ontario. Her pharmaceutical career has included positions in regulatory affairs, biometrics,

sales management, research, marketing, and general management. Deborah has led the launch of several leading biologic

products in both the US and Canada.

2011 Faculty

In her current capacity as President of EMD Serono Canada, she oversees one of Canada’s most

successful commercial biotechnology companies, offering or developing niche prescription drugs in

the areas of neurodegenerative disease, endocrinology, rheumatology, oncology and fertility. They

have been named a GTA Top Employer in both 2009 and 2010.

Deborah serves on the Executive Committee and Board of Rx&D, chairs the Industry Practices

Committee, and is a past board and executive committee member of BIOTECanada.

In addition to her corporate responsibilities, Deborah is involved in her community and several

charitable organization. She is a founding member of Women Against MS (WAMS) which is a special

fundraising group of the MS Society, the Toronto Humane Society, McMaster Children’s Hospital, and

the three organizations that EMD Serono actively supports—the Mississauga Food Bank, Halton

Women’s Place and the Halton Learning Foundation.

JILL DONAHUE, Hba, MadEdSpeaker, Writer, Behaviour Change Consultant to Pharma

Excellerate

Jill Donahue Hba, MAded, author of PERSUASION Rx: How to Influence Ethically (now CCPE’s

most popular course), is fascinated with behaviour change in healthcare. Through her

energizing keynotes, workshops, coaching and consulting, she brings the ah-ha’s to how to

influence others—health care professionals, patients, your audience, your team, even your

spouse. From ‘uninterested’ to ‘on board’ she has tips for every step of the way.

While Jill brings a strong academic background to her work, what marvels her pharma clients is

her talent to translate the theory of behaviour change to practical application to help pharma

professionals from all departments and health care professionals influence more effectively.

Says one client:

“Jill is the guru of behaviour change—the “go to” company for those in healthcare to learn how

to influence behaviour change and improve patient outcomes.”

Founder and chair of Bricks and Books, the “do good, feel good” leadership event of the year for pharmaceutical industry

professionals, Jill and her volunteer team are creating good news headlines for the pharma community in Canada. They

are aiming to build two schools in Nepal through this popular conference built by and for pharma. Mark your calendars for

Oct 5, right here at Hilton Garden Inn. Early bird registration opens today March 30 at www.bricksandbooksevent.com.

For insight on the ideas and solutions she offers, visit www.excellerate.ca. Look for the “Loot Bag" where you can download

a FREE self-reflection exercise and article “Are you an influencer? How to Influence in Pharma.”

PAT FORSYTHENeuroscience Business Unit Director

Allergan Inc.

Pat Forsythe,Neuroscience Business Director at Allergan Canada has over 20 years of sales and

marketing experience in the Canadian Pharmaceutical industry in a range of therapeutic areas from

Specialty Biotech to traditional Primary Care. Prior to Allergan, Pat worked with Altana Pharma in

the Gastroenterology and Respiratory categories and with Roche in Hepatitis, Cardiovasculars and

Antimicrobials. He started his career with the Upjohn Company of Canada.

Pat's sales and marketing career has been characterized by a strong focus on a customer centric

approach balanced with the reality of the business needs. His work has been characterized by

constant innovation and an entrepreneurial approach to meeting customer needs.

Pat has been involved in 12 product launches and is currently working with his team to prepare for

additional launches in 2011 through 2014..

MORRIS GOODMANChairman of the Board

Pharmascience inc.

Born in Montreal on September 14, 1931, Morris Goodman is Chairman of the Board of Pharmascience

Inc., a company that he co-founded in June 1983. Morris Goodman graduated from the Faculty of

Pharmacy at the University of Montreal in 1953 at the age of twenty-one, the youngest graduate of that

faculty at that time, and obtained the University of Montreal's Prize for Success.

Upon obtaining his degree, Morris Goodman chose to embark on the industry side of pharmacy, and

quickly obtained distribution rights from several international pharmaceutical companies in order to bring

their products to the Canadian marketplace. Specializing in the therapeutic areas of dermatology and

tuberculosis, Morris Goodman marketed and sold these products in Canada under the company name

of Winley-Morris Co. Ltd.

In 1971, Morris Goodman approached a California-based company named International Chemical &

Nuclear Corporation (which subsequently became ICN), to become their Canadian distributor of L-Dopa.

Impressed with his innovative approach, ICN negotiated to purchase Winley-Morris and established Morris Goodman as CEO of ICN

Canada. After successfully running ICN for over ten years, Morris Goodman left ICN in 1983 to begin a brand new innovative generic

enterprise, Pharmascience Inc.

As Co-Founder & Chairman of the Board of Pharmascience Inc., Morris Goodman has been at the forefront of the explosive growth

and development of Pharmascience, leading it to its current standing as one of the top three generic pharmaceutical companies in

Canada.

As one of Canada’s leading entrepreneurs, Morris Goodman is committed to “Creating The Difference” for the healthcare industry in

Canada and worldwide.

DOUG GRANTSenior Vice President and Head, Corporate Affairs

Bayer Inc.

Doug Grant is the Senior Vice President and Head of Corporate Affairs at Bayer Inc. In his role, Doug

is responsible for providing management, leadership and strategic direction for Communications,

Trade Relations, Contracts, Pricing, Reimbursement, Federal and Provincial Government Affairs, as

well as overseeing the Hematology business unit.

Doug began his career at Bayer in 2001 and has held numerous positions within the organization.

Prior to joining Bayer, Doug held various senior management roles at Bristol-Myers Squibb Canada,

Pfizer Canada and Marion Merrell Dow.

After three years of being the Vice-Chair of Canada’s Research-Based Pharmaceutical Companies'

(Rx&D) Provincial Affairs Committee, Doug is moving to a new role with the Strategic Advisory Group

of Rx&D. Rx&D is the national association representing more than 22,000 employees working for

over 50 pharmaceuticals companies across Canada. In addition, Doug is returning for another term

as a MEDEC (Medical Device Industry in Canada) Board Member. MEDEC is the national

association representing more than 35,000 employees working for over 1,500 corporate facilities.

Doug is a graduate of York University and is an active member of several industry associations. He is also a past member of

several industry boards including the Institute of Health Economics and the Council for Continuing Pharmaceutical Education.

ROBIN HUNTERVice President, Critical Care

LEO Pharma

Founded more than 100 years ago, LEO Pharma is a research-based, specialty pharmaceutical company committed to thediscovery and development of novel drugs. LEO Pharma is wholly owned by the LEO Foundation, an independent and privateinstitution headquartered in Denmark.

Robin Hunter has over 17 years in the pharmaceutical industry and joined LEO in Nov. 2010. Priorto joining LEO, Robin spent 12 years at Roche in various roles of increasing responsibility, all ofwhich had a contractual clause obligating him to laugh at Ronnie Miller’s jokes.

He has never had a negative comment from PAAB. In fact, all his promotional tools are preapproved with the PAAB logo and are hand delivered by the Commish. The Rx&D Code of Conductwas lifted word for word off of his grade 10 report card. Although the laws of physics still don’t applyto him, they can be administered subcutaneously as outlined in the prescribing information. Robinstill struggles with the spelling of PLA. Health Canada doesn’t send him a clarifax, they send him atext that always ends with LOL.

DR. BRIAN JAHNDirector, Hematology Business Unit

Hoffmann-La Roche

Dr Brian Jahn, Director of the Hematology Business Unit of Hoffmann-La Roche, leads the marketing

and sales of Rituxan® (rituximab) in Canada. Since joining the organization in 1998, Brian has

fulfilled various marketing, sales management, and medical roles in Roche, and has been involved

in the successful launch and growth of several antiviral agents, transplant immunosuppressants and

anticancer biologics. Throughout the decade prior to joining Roche, Brian was a consultant to the

Canadian pharmaceutical industry, and was involved in academia and the delivery of patient care at

the University of Toronto and several institutions in the US.

MARC LALANDELearning and Change Consultant

Learning Andrago Inc.

Marc is Learning Andrago Inc’s Learning and Change Consultant. Marc began his career in the

pharmaceutical sector, as a representative for Lederle Laboratories, in 1984. He worked for Abbott

Labs as a Pharmacy and Medical Representative from 1985 to 1988. In this role, he was also tasked

with field training new representatives. He joined Glaxo in 1988 and worked as a Training Associate

and Professional Hospital Representative before becoming Hospital Regional Sales Manager. He

spent over 11 years with Berlex working in a variety of roles including Sales Management, Product

and Portfolio Management, Professional Education Management and Sales Training and

development management. Marc was General Manager of CCPE from 2004 to 2008, he had served

as a volunteer on the CCPE Board of Directors since 2001.

Hallmarks of his career are the many awards he has received, his personal commitment to

continuous learning, and creating multiple networking forums of discussions for pharmaceutical

sales executives, trainers and HR specialists in Canada.

In his consulting role, Marc is often mandated to investigate various competency and attitude gaps to recommend measures to

enhance performance and accelerate changes.

KEVIN LESHUKCanadian General Manager

Celgene

Kevin Leshuk began his career in the pharmaceutical/biotech industry in the early 1990’s with Adria Oncology. He is presently

the Canadian General Manager for Celgene; a multinational biopharmaceutical company focused on the discovery, development

and commercialization of products for the treatment of cancer and other severe, immune-inflammatory conditions. Through his

career, Kevin has had the tremendous good fortune to work within some of the leading Canadian

pharmaceutical companies that have provided the opportunity to work in multiple therapeutic areas.

Over the past 20 years, Kevin has held management and senior management roles with specific

responsibilities in Sales, Marketing, Key Account Management and most recently Market Access.

MARK McELWAINVice President, Account Services

kbs+p Toronto

Mark McElwain is Vice President, Account Services at kbs+p Toronto (formerly Allard Johnson

Communications) where he heads the wellness division, which develops advertising and interactive

programs for pharma and other healthcare clients.

Prior to joining Allard Johnson, Mark was Commissioner/CEO of the Pharmaceutical Advertising

Advisory Board (PAAB). During his tenure at PAAB, he worked to improve service turnaround

times, reform the complaints process, and together with stakeholders to raise PAAB's profile in

industry self-regulation.

Mark started his career as a health economist and worked at senior levels in both federal and

Ontario governments. He has master’s degrees from the London School of Economics and from

Queen’s University.

EILEEN McMAHONPartner,

Torys LLP

Eileen McMahon is Co-Chair of the Intellectual Property and Food and Drug Regulatory practices

at Torys LLP. Torys is a law firm with offices in Toronto, New York and Calgary. Eileen and her firm

act for many leading pharmaceutical, biotechnology and medical device companies. Eileen is a

lawyer and is a registered patent agent in the United States and Canada.

CLAUDE PERRONVice President and General Manager

Shire Canada Inc.

Claude Perron graduated from Université de Montréal with a BSc in Biochemistry in 1982. In 1983,

Claude started in the Pharmaceutical Industry for Burroughs Wellcome as a Sales Representative

covering both general practitioners and specialists until 1987. He was then assigned to manage

the Tender and Reimbursement business until 1988. For the next four years, Claude was assigned

the role of District Sales Manager and in 1992 as Product Manager responsible for the antiviral

therapeutic area.

When Glaxo acquired Wellcome in 1995, Claude accepted a position in the HIV Therapeutic Area as Senior Product Manager

responsible to launch 3TC® in Canada. He held different management positions in this rapidly-evolving therapeutic area up to

Group Business Manager in 2001.

Claude then accepted the move to Shire as Vice-President of Sales & Marketing where his initial responsibilities were to build

a new commercial team and help build Shire’s presence in Canada. After Shire went though global restructuring in late 2003,

he accepted the position of Vice-President and General Manager for the Canadian Operations in early 2004.

Claude is a Board Member of Rx&D and Chair of the Quebec Regional Committee. He sits on the Board of the Montreal

Children’s Hospital Foundation and act as a volunteer for the annual United Way Campaign for the Pharma Division.

DR. SHAFIQ QAADRIGeneral Practitioner

MPP (Ontario), Parliamentary Assistant to the Minister of Health Promotion

Dr. Shafiq Qaadri is a Toronto family physician, Continuing Medical Education (CME) lecturer,

medical writer and broadcaster. He wrote a column for doctors in The Medical Post, and currently

writes for The Globe and Mail, Canada’s national newspaper. He has logged more than 1,000

radio and TV shows across Canada.

He is a Designated Medical Practitioner (DMP) of the Government of Canada, and a leader in

making health information understandable to the public and physicians alike.

Dr. Qaadri has delivered more than 180 medical lectures, and published more than 700 articles,

on a wide range of topics. He is a presenter for the Heart and Stroke Foundation, Canadian

Diabetes Association, and the Ontario Lung Association.

He is the author of the international-selling health manual for baby-boomer men, The Testosterone

Factor: A Practical Guide to Vitality and Virility, Naturally, which is now available in five countries in four languages.

A long-time advocate of quality public healthcare and a compassionate society, Dr. Qaadri was elected to the Government of

Ontario as the Member of Provincial Parliament (MPP) for Etobicoke North in October 2003. He was re-elected as the MPPfor

Etobicoke North in October 2007. He is the Chair of the Parliamentary Standing Committee on Social Policy.

Educated at Upper Canada College, he graduated from the University of Toronto Medical School in 1988. During his academic

career, he won numerous awards and scholarships, including a Canadian National Debating Championship, an English-

Speaking Union Essay Prize to Oxford University, a Medical Research Council Scholarship in Clinical Neurosurgery, and a

Senator Thompson Fellowship at the University of Pennsylvania.

He is a member of the Healthcare Policy Group of the Council of State Governments (New York), an American-based think-

tank which offers counselling to government, advising states and organizations navigating the waters of universal coverage.

DAVID RENWICKDirector,

Pangaea Group

David Renwick has more than 20 years of experience in sales, marketing and general

management in the Canadian pharmaceutical industry. He has held several progressive

leadership roles with both large and small companies and has helped lead the growth of a

specialty pharmaceutical company from start-up as Director of Sales and Marketing. As a Director

of the Pangaea Group and capitalizing on his diverse background and breadth of experience,

David is able to bring clients a wide array of commercial solutions at all stages of both company

and brand life-cycles. David specializes in patient adherence, audience segmentation, targeting

and resource optimization.

THOMAS SCHLADERGeneral Manager

Valeant

Thomas Schlader has a solid track record and developed a wealth of expertise with more than 32

years of experience in the pharmaceutical industry, acquired within a variety of organizations such

as Merck Frosst, Rhône Poulenc Rorer, Quebec’s Ministry of Industry and Commerce and IAF

Biovac. Tom holds a Bachelor degree in Biology from Laval University in Quebec City.

Tom has been an active participant in the success of Valeant Canada for more than 18 years

spending 10 years as Vice President, Sales & Marketing and eight years as President. The

Canadian division, under his guidance, became one of the top performing divisoins within Valeant

for many years. Tom is responsible for three companies (Valeant Canada, Head Office in Quebec,

Laboratoire Dr Renaud, Head Office in Quebec and VitalScience, Head Office in Ontario) including

two manufacturing sites in Quebec and leads an executive team of eight Senior Directors and VPs

and more than 450 employees in Canada

Among Tom’s and his team’s numerous accomplishments and achievements are the merger

between Biovail Canada and Valeant Pharmaceuticals International, the negotiation of major deals for Valeant Canada such as

product acquisitions, in-licensing and company acquisitions and meeting and surpassing of financial objectives on a consistent

basis. Under his leadership, Valeant Canada has been among Canada’s faster growing companies in the pharmaceutical

industry for a number of years. The company has been awarded IMS Award for Team Excellence in Pharmaceutical Marketing

by The Chronicle of Health Marketing and the Hall of Fame Two Chambers of Commerce in Quebec have awarded the company

distinctions such as Company of the Year, Manufacturing Company of the Year for more than 100 employees, Human

Resources Management Distinction prize and Diversity Management distinction prize.

Tom is also an accomplished watercolor painter, having presented two previews at art galleries. Cooking and wine tasting are

two of his joys in life.

ANDREAS SEIGERMarkering Director, Diabetes Care

Novo Nordisk Canada Inc.

Andreas joined Novo Nordisk more than 15 years ago at the Regional Office for Europe East and

South America in Vienna where he held Finance, IT and customer service positions. In 1999 he

was promoted to the European Head Office where he held project management and supply-chain

management roles. After an assignment as a European Product Manager he was promoted to

Commercial Director in the European Head Office in Zurich.

In October 2006, Andreas joined the US Diabetes Marketing team as Project Director responsible

for brand acceleration programs and non-personal marketing support initiatives. Before moving to

Canada and heading up Diabetes Marketing and Market Access, Andreas was in the field as a

District Business Manager in Brooklyn, NY from November 2007.

Andreas holds a Masters Degree in Business Administration from the University of Economics,

Business Administration and Commerce in Vienna.

MITCHELL SHANNONPresident

Chronicle Companies

Mitchell Shannon is CEO and co-founder of Chronicle Companies, preferred information provider

to Canada’s medical specialists, and a leading provider of business intelligence to Canadian

pharmaceutical marketers. Chronicle is the organizing corporate partner of the National

Pharmaceutical Congress. Since 1995, the company has served the life sciences industry through

its business to business publications, The Chronicle of Healthcare Marketing™, Drug Rep

Chronicle and coming later this year, Dental Industry Chronicle. This year marks the ninth annual

presentation of the Canadian Healthcare Marketing Hall of Fame Awards, a program initiated by

Chronicle as a means of honoring the industry’s builders.

Mitch is the publisher of Chronicle’s nationally-distributed journals for the health specialties, including dermatology, dentistry and

psychiatry. He is a director of the Chronic Obstructive Pulmonary Disease Association and is a founding director of a new

initiative intended to advocate for diabetes patients and resources, “D-Minus. the Partnership to Prevent Diabetes.” He blogs

at www.mitchellshannon.com

DAVID SKINNERPresident

Consumer Health Products Canada

Mr. Skinner is a biochemist working in the healthcare field. After having received a BSc (Hon), he

began his career conducting laboratory research for the International Joint Commission prior to an

appointment to the National Research Council of Canada. He spent his early career conducting

practical research.

In 1979, Mr. Skinner was invited to join Consumer Health Products Canada (formerly NDMAC) with

Scientific and Regulatory Affairs responsibilities. Since 1983, he has held the position of President

for this National Trade Organization. He has published research papers in a broad range of

periodicals and has served on several advisory committees to governments, including Federal

Committees to develop National Health Care policies. He has been involved in major healthcare

reform initiatives such as Provincial Health Commissions, Dr. Gagnon’s review of Drug Regulatory

Reform, Public service management audits and the National Advisory Committee on Natural

Health Products.

MICHAEL J. TREMBLAYPresident

Astellas Pharma Canada, Inc.

Michael has been in the pharmaceutical business for over 30 years and has worked for a number

of primary care and specialty based companies. His experience spans not only Sales and

Marketing but also includes time spent in New Business Development, Training and Customer

Relationship Management.

He was appointed as President of Astellas Pharma Canada in July 2010 and is active in Rx&D.

He is a member of their Board of Directors and is Chair of the Prairies Committee.

Michael was inducted into the Canadian Healthcare Marketing Hall of Fame in 2010.

He is an avid, but not very accomplished golfer and enjoys both cooking and wine tasting. He has

been married to his friend and confidant, Jo-Anne for 34 years and has two grown up daughters

and three granddogs.

RUSSELL WILLIAMSPresident

Canada’s Research-based Pharmaceutical Companies (Rx&D)

Russell Williams is a passionate advocate for innovation in health care and in economic

development. Since joining Rx&D in March 2004, Mr. Williams has promoted policies that improve

patient outcomes by expanding patient choice and access to new medicines and vaccines. He

works tirelessly to ensure that Canada is a world leader in attracting biopharmaceutical

investments, which are key components of the knowledge-based economy.

Under Mr. Williams’ leadership, the association’s Code of Ethical Practices has been significantly

enhanced to ensure that all member companies adhere to the highest standards of ethics. He has

participated actively in numerous provincial working groups and task forces aimed at improving

the partnership between industry, governments and stakeholders.

Prior to joining Rx&D, Mr. Williams had a successful career in provincial politics and community service. For 15 years, he represented the Montreal

riding of Nelligan in the National Assembly of Quebec. During his career as Liberal MNA, he led numerous public policy debates on important and

complex issues, such as the role of government in research and development (R&D), compensation for victims of contaminated blood, linguistic

policy, access to services for the disabled, and pre-hospital emergency services. He is well known for his dedication and perseverance as an advocate

for individual rights and government services focused on the needs of its citizens. He continues active volunteer involvement in palliative care.